Best responses to treatment
| Response . | All patients . | High-dose dexamethasone patients . | ||||
|---|---|---|---|---|---|---|
| thal/dex (n = 183), n (%) . | len/dex (n = 228), n (%) . | P . | thal/dex (n = 72), n (%) . | len/dex (n = 72), n (%) . | P . | |
| CR or VGPR | 22 (12.0) | 78 (34.2) | < .001 | 7 (9.7) | 36 (50.0) | < .001 |
| PR or better | 112 (61.2) | 183 (80.3) | < .001 | 44 (61.1) | 65 (90.3) | < .001 |
| CR | 6 (3.3) | 31 (13.6) | < .001 | 2 (2.8) | 16 (22.2) | < .001 |
| VGPR | 16 (8.7) | 47 (20.6) | < .001 | 5 (6.9) | 20 (27.8) | .001 |
| PR | 90 (49.2) | 105 (46.1) | .528 | 37 (51.4) | 29 (40.3) | .181 |
| SD | 42 (22.9) | 26 (11.4) | .002 | 21 (29.2) | 3 (4.2) | < .001 |
| PD | 1 (0.6) | 5 (2.2) | .232 | 1 (1.4) | 1 (1.4) | > .999 |
| NA | 28 (15.3) | 14 (6.1) | — | 6 (8.3) | 3 (4.2) | — |
| Response . | All patients . | High-dose dexamethasone patients . | ||||
|---|---|---|---|---|---|---|
| thal/dex (n = 183), n (%) . | len/dex (n = 228), n (%) . | P . | thal/dex (n = 72), n (%) . | len/dex (n = 72), n (%) . | P . | |
| CR or VGPR | 22 (12.0) | 78 (34.2) | < .001 | 7 (9.7) | 36 (50.0) | < .001 |
| PR or better | 112 (61.2) | 183 (80.3) | < .001 | 44 (61.1) | 65 (90.3) | < .001 |
| CR | 6 (3.3) | 31 (13.6) | < .001 | 2 (2.8) | 16 (22.2) | < .001 |
| VGPR | 16 (8.7) | 47 (20.6) | < .001 | 5 (6.9) | 20 (27.8) | .001 |
| PR | 90 (49.2) | 105 (46.1) | .528 | 37 (51.4) | 29 (40.3) | .181 |
| SD | 42 (22.9) | 26 (11.4) | .002 | 21 (29.2) | 3 (4.2) | < .001 |
| PD | 1 (0.6) | 5 (2.2) | .232 | 1 (1.4) | 1 (1.4) | > .999 |
| NA | 28 (15.3) | 14 (6.1) | — | 6 (8.3) | 3 (4.2) | — |
Percentages may not total 100 because of rounding.
SD indicates stable disease; PD, progressive disease; NA, not available; and —, not applicable.